Literature DB >> 31677696

Bipolar spectrum disorder: What evidence for pharmacological treatment? A systematic review.

Vincent Hede1, Sophie Favre2, Jean-Michel Aubry3, Hélène Richard-Lepouriel4.   

Abstract

BACKGROUND AND OBJECTIVES: Bipolar spectrum disorder (BSD) is an extended concept of bipolar disorder (BD) that includes conditions that do not fulfill the criteria. There is no recommendation today about its treatment. We reviewed relevant literature focusing on pharmacological treatments, looking for high-strength evidence leading to guidelines.
METHODOLOGY: A literature search was conducted using MedLine / PubMed database and Google Scholar up to September 2018. Search words were related to BSD and pharmacological treatment.
RESULTS: The literature search yielded 621 articles. Out of these, 35 articles met our selection criteria. There was limited high quality data. Only one randomized control trial (RCT) and one randomized open label trial were found. Most studies used different definition of BSD.
CONCLUSIONS: There is a considerable lack of data and no evidence supporting efficacy of pharmacological treatment for BSD. There is a need for a consensus on the definition of BSD and more evidence studies to evaluate drug's effectiveness in this condition.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Agitated depression; Mood stabilizer; Pharmacological treatment; Subthreshold

Mesh:

Year:  2019        PMID: 31677696     DOI: 10.1016/j.psychres.2019.112627

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  1 in total

1.  Deficient LEF1 expression is associated with lithium resistance and hyperexcitability in neurons derived from bipolar disorder patients.

Authors:  Renata Santos; Sara B Linker; Shani Stern; Ana P D Mendes; Maxim N Shokhirev; Galina Erikson; Lynne Randolph-Moore; Vipula Racha; Yeni Kim; John R Kelsoe; Anne G Bang; M Alda; Maria C Marchetto; Fred H Gage
Journal:  Mol Psychiatry       Date:  2021-01-04       Impact factor: 13.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.